Fedratinib

Fedratinib Reference Standards Supplier and Manufacturer in India

Fedratinib is a small molecule inhibitor of the Janus kinase 2 (JAK2) enzyme, which is a key player in the signaling pathways involved in the production and regulation of blood cells. It was developed as a potential treatment for myeloproliferative neoplasms (MPNs), a group of rare blood cancers characterized by the overproduction of one or more types of blood cells. Fedratinib, also known by its brand name Inrebic, was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. Myelofibrosis is a type of MPN in which excessive scar tissue (fibrosis) forms in the bone marrow, leading to an enlarged spleen and liver, as well as various other symptoms.

As a JAK2 inhibitor, fedratinib works by blocking the activity of the JAK2 enzyme, which is often overactive in cells with certain mutations associated with MPNs. By inhibiting JAK2, fedratinib can help reduce the overproduction of blood cells and the accompanying symptoms of myelofibrosis, such as an enlarged spleen, fatigue, night sweats, and bone pain.

Aquigen Bio Sciences is a leading supplier and manufacturer of fedratinib reference standards in India. Our team of experienced chemists and quality control professionals ensure that our fedratinib reference standards meet the highest standards of purity, quality, and regulatory compliance. We have established robust manufacturing processes and strict quality control measures to provide our customers with reliable and consistent products.